In a report released today, Roy Buchanan from JMP Securities maintained a Buy rating on PolyPid (PYPD – Research Report), with a price target of $3.00. The company’s shares opened today at $1.30.
According to TipRanks, Buchanan is an analyst with an average return of -14.5% and a 30.12% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as PolyPid, Arbutus Biopharma, and Enanta Pharmaceuticals.
PolyPid has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.77 and a one-year low of $3.92. Currently, PolyPid has an average volume of 21.69K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company’s proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
Read More on PYPD:
- Profound Medical Provides TULSA-PRO® Reimbursement Update
- Here’s Why Rocket Lab USA Stock (NASDAQ:RKLB) is Up Today
- Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
- RUGBY RESOURCES LTD. GRANTS RESTRICTED SHARE UNITS AND REPRICES AND GRANTS INCENTIVE STOCK OPTIONS
- Here’s Why NOC Stock is Reasonably Valued despite Recent Rally
